1/15
08:02 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
1/9
08:02 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Neutral
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
1/8
07:05 pm
eprx
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
1/8
09:53 am
eprx
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
High
Report
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
1/8
07:34 am
eprx
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
High
Report
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
12/13
01:10 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at
Wall
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at
Wall
12/12
05:52 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
12/4
10:20 pm
eprx
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why [Yahoo! Finance]
Medium
Report
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why [Yahoo! Finance]
11/23
02:11 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
Low
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
11/17
05:56 am
eprx
Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% [Yahoo! Finance]
Low
Report
Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% [Yahoo! Finance]
11/15
01:42 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at
Wall
Low
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at
Wall
11/4
05:28 pm
eprx
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results [Canadian Business Journal (Canada)]
Medium
Report
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results [Canadian Business Journal (Canada)]
11/4
04:39 pm
eprx
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Medium
Report
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
10/30
07:50 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Leede Financial to a "strong-buy" rating.
Low
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Leede Financial to a "strong-buy" rating.